Martin J Landray
Overview
Explore the profile of Martin J Landray including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
12205
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Judge P, Tuttle K, Staplin N, Hauske S, Zhu D, Sardell R, et al.
Nephrol Dial Transplant
. 2024 Nov;
PMID: 39533115
Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium...
2.
Herrington W, Staplin N, Agrawal N, Wanner C, Green J, Hauske S, et al.
N Engl J Med
. 2024 Oct;
392(8):777-787.
PMID: 39453837
Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial...
3.
Christensen J, Johansen N, Janstrup K, Modin D, Skaarup K, Nealon J, et al.
J Infect
. 2024 Sep;
89(5):106276.
PMID: 39303788
Objectives: Morning influenza vaccination enhances antibody response. In this post hoc analysis of the DANFLU-1 trial, we sought to evaluate the association between time of day for vaccination (ToV) and...
4.
Mayne K, Sardell R, Staplin N, Judge P, Zhu D, Sammons E, et al.
Nephrol Dial Transplant
. 2024 Sep;
PMID: 39277784
Background And Hypothesis: Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout...
5.
Bartholdy K, Johansen N, Janstrup K, Modin D, Nealon J, Samson S, et al.
J Am Coll Cardiol
. 2024 Sep;
PMID: 39217544
No abstract available.
6.
Christensen J, Johansen N, Modin D, Janstrup K, Nealon J, Samson S, et al.
Circ Cardiovasc Qual Outcomes
. 2024 Aug;
18(2):e011496.
PMID: 39215646
Background: Influenza vaccination reduces the risk of adverse outcomes in patients with cardiovascular disease (CVD). We sought to evaluate whether the presence of CVD modified the relative effectiveness of the...
7.
Pessoa-Amorim G, Goldacre R, Crichton C, Stevens W, Nunn M, King A, et al.
Trials
. 2024 Jul;
25(1):429.
PMID: 38951929
Background: Randomised trials are essential to reliably assess medical interventions. Nevertheless, interpretation of such studies, particularly when considering absolute effects, is enhanced by understanding how the trial population may differ...
8.
Mayne K, Sardell R, Staplin N, Judge P, Zhu D, Sammons E, et al.
Clin J Am Soc Nephrol
. 2024 Jul;
PMID: 38949880
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recommended treatment for adults with chronic kidney disease (CKD), but uncertainty exists regarding their use in patients with frailty and/or multimorbidity, among whom polypharmacy...
9.
Hojbjerg Lassen M, Johansen N, Modin D, Nealon J, Samson S, Dufournet M, et al.
Diabetes Obes Metab
. 2024 Apr;
26(5):1821-1829.
PMID: 38586966
Aim: High-dose quadrivalent influenza vaccine (QIV-HD) has been shown to be more effective than standard-dose (QIV-SD) in reducing influenza infection, but whether diabetes status affects relative vaccine effectiveness (rVE) is...
10.
Johansen N, Modin D, Nealon J, Samson S, Salamand C, Loiacono M, et al.
NEJM Evid
. 2024 Feb;
2(2):EVIDoa2200206.
PMID: 38320035
BACKGROUND: The relative vaccine effectiveness (rVE) of high-dose quadrivalent influenza vaccines (QIV-HD) versus standard-dose quadrivalent influenza vaccines (QIV-SD) against hospitalizations and mortality in the general older population has not been...